Porphyrins, Quantitative, 24 Hour, Urine
Porphyrins are intermediate in the heme biosynthetic pathway. Enzyme defects in this pathway lead to reduced heme synthesis, accumulation of porphyrins or their precursors, and the clinical syndromes collectively termed porphyrias. Classification is based on the site of overproduction (erythropoietic vs. hepatic) and on clinical manifestations (acute neurovisceral vs. chronic cutaneous). Diagnosis relies on biochemical testing to detect and characterize abnormal porphyrin accumulation in plasma, erythrocytes, urine, or feces.
Erythropoietic porphyrias: CEP results from uroporphyrinogen III synthase deficiency, manifesting in infancy with severe photosensitivity, hemolytic anemia, and red-brown urine. EPP arises from ferrochelatase deficiency, leading to accumulation of protoporphyrin IX in red cells, typically presenting in childhood with photosensitivity but no blistering.
Hepatic porphyrias: Acute intermittent porphyria (AIP), HCP, and VP are characterized by neurovisceral attacks including severe abdominal pain, neuropathy, and seizures. Cutaneous manifestations are rare in AIP but present in VP and HCP. Porphyria cutanea tarda (PCT), the most common type, is due to hepatic inhibition of uroporphyrinogen decarboxylase, leading to blistering photosensitivity, hyperpigmentation, and scarring on sun-exposed areas. Chronic progression may result in cirrhosis and hepatocellular carcinoma.
While biochemical testing is essential for screening and diagnosis, genetic confirmation and correlation with clinical features are recommended for accurate classification.
- Screening for suspected porphyrias
- Differentiation of acute neurovisceral vs. chronic cutaneous porphyrias
- As an aid in the diagnosis of porphyria cutanea tarda and other hepatic porphyrias
- Treatment monitoring and disease management
Increased in:
- Acute intermittent porphyria (AIP)
- Porphyria cutanea tarda (PCT)
- Erythropoietic protoporphyria (EPP)
- Congenital erythropoietic porphyria (CEP)
- Hereditary coproporphyria (HCP)
- Variegate porphyria (VP)
- Cirrhosis
- Hepatitis
- Liver tumors
- Alcoholism
- Iron deficiency anemia
- Acute liver failure
Decreased in:
- Hemochromatosis
- Acute myeloid leukemia
- Vitamin B6, Vitamin C deficiency
- Chronic renal failure
≤ 1.0 mcg/dL (plasma total porphyrins)
24 hour collected urine in a sterile container.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Compr Physiol. 2013 Jan;3(1):365-401. [PMID: 23720291]
- Molecules. 2019 Jul 23;24(14):2669. [PMID: 31340553]
- Gastroenterology. 2019 Aug;157(2):365-381.e4. [PMID: 31085196]
- Biomed Pharmacother. 2023 Aug;164:114933. [PMID: 37236030]
- J Clin Lab Invest. 2000 Nov;60(7):561-79. [PMID: 11202050]